Sinovac

Haidian, China Founded: 2001 • Age: 25 yrs Acquired By SAIF Partners
Vaccines against various infectious diseases are developed by Sinovac.
Annual revenue - Latest available
Total funding - 7 rounds
Employees - Tracked headcount
Investors 6 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Sinovac

Sinovac is a company based in Haidian (China) founded in 2001 was acquired by SAIF Partners in June 2017. Sinovac operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.

  • Headquarter Haidian, China
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    $515 M (USD), Post-IPO

    Dec 07, 2020

  • Investors
  • Employee Count
    Not available
  • Acquired by
    SAIF Partners

    (Jun 26, 2017)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Sinovac

Investors in Sinovac

Sinovac has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Sino Biopharmaceutical, Advantech Capital and Vivo Capital.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Locked Locked Locked
Venture capital and private equity firm
Locked Locked Locked
-
Locked Locked Locked
Premium access

Investor details for Sinovac

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Sinovac

Investments
Premium access

Investment portfolio details for Sinovac

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Sinovac

Premium access

Detailed financials for Sinovac

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Sinovac Comparisons

Sinovac Primary company
Description
Vaccines against various infectious diseases are developed b...
Location
Haidian, China
Founded Year
2001
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Sinovac

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Sinovac

Sinovac operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Clinical diagnostics and drug discovery for immune diseases are provided.
Locked Locked Locked
mRNA-based therapeutics for diseases including cancer and infections are developed.
Locked Locked Locked
Developer of novel protein-based therapeutics using machine learning and biological engineering
Locked Locked Locked
Developer of immunotherapies for the treatment of infectious diseases and cancer
Locked Locked Locked
Developer of biologics to treat hepatitis B infection
Locked Locked Locked
VBI Vaccines is engaged in developing vaccines and immunotherapeutics.
Premium access

Detailed competitors of Sinovac

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Sinovac

Premium access

Complete news archive for Sinovac

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sinovac

Sinovac was founded in 2001 and raised its 1st funding round 3 years after it was founded.

Sinovac is headquartered in Haidian, China. It is registered at Haidian, Beijing, China.

Sinovac was established in 2001 in Haidian, China, within the biotechnology sector focused on vaccine development. Vaccines have been produced for hepatitis A and B, seasonal influenza, H5N1 avian flu, H1N1 swine flu, mumps, and canine rabies. The Panflu.1 H1N1 vaccine was manufactured for the Chinese Central Government. Ongoing efforts include pipeline vaccines for enterovirus 71, pneumococcal conjugate and polysaccharides, and rubella, addressing key public health needs.

Sinovac's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.

Sinovac has 6 investors. Key investors include Sino Biopharmaceutical, Advantech Capital, Vivo Capital, Ministry of Science and Technology of the People's Republic of China, and CBC Group.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available